Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Praxis Precision Medicines Inc (NQ: PRAX )

66.30 +5.16 (+8.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Praxis Precision Medicines Inc

< Previous 1 2 Next >
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
Ambit to showcase its prevalence projection approach, co-developed with Praxis, for rare developmental and epileptic encephalopathies (DEEs) as a Platform Presentation at this year's annual Child... 
Via Newswire.com
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.